Overall survival in children with acute myeloid leukemia (AML) has improved to 60-70%. However, after disease recurrence, the likelihood of long-term survival is poor (20-30%). Several subtypes of childhood AML are at high risk of relapse including a group with internal tandem duplication (ITD) mutations in the receptor tyrosine kinase FLT3. Children with newly diagnosed FLT3-ITD-postive AML have an overall survival of 40% when treated with induction therapy followed by 3-4 courses of chemotherapy, whereas worse survival rates have been reported in adults with FLT3-ITD mutated AML. FLT3-ITD mutations occur in about 15% of pediatric AML and more than 30% of adult AML. Further significant improvements in long-term survival of FLT3-ITD-positive AML are not expected with conventional chemotherapy alone and new therapeutic strategies are needed. In this proposal, we outline three related projects to circumvent and treat drug-resistant FLT3-ITD- positive AML including:
(Aim 1) to determine the effects of sorafenib in combination with crenolanib on drug efficacy, toxicity, PK, PD and resistance profiles in relapsed/refractory pediatric FLT3-ITD+ AML, with our hypothesis that optimal FLT3 inhibition is required to suppress the emergence of TKI-resistant secondary TKD mutations;
(Aim 2) to determine the role of the Tec kinase BMX in sorafenib resistance, with our hypothesis that during FLT3 inhibition, BMX upregulation and activation provides a compensatory signaling pathway that confers resistance to sorafenib;
and (Aim 3) to identify effective sorafenib combinations in FLT3-ITD+ AML. In the latter Aim, the translational potential of ibrutinib, a lead BMX inhibitor, when given in combination with sorafenib, will be evaluated, with our hypothesis that ibrutinib will suppress BMX activity during sorafenib treatment and in combination will be an effective treatment strategy for FLT3-ITD+ AML. Our strategy represents a continuous interplay between laboratory in vitro and in vivo experimental approaches and clinical observations, and we hypothesize that this approach will lead to the identification of important, previously unrecognized mechanisms of TKI resistance as well as to the future discovery of novel treatment strategies for childhood AML with improved outcome.

Public Health Relevance

Although overall survival in children with acute myeloid leukemia (AML) has improved to 60-70%, the likelihood of long-term survival is exceptionally poor after relapse (20-30%). Further significant improvements in long- term outcome are not expected with conventional therapy alone. Our studies are of direct human relevance as they will lead to the rational incorporation of novel tyrosine kinase inhibitors in treatment strategies for childhood AML.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA138744-10
Application #
9763457
Study Section
Developmental Therapeutics Study Section (DT)
Program Officer
O'Hayre, Morgan
Project Start
2009-04-01
Project End
2020-08-31
Budget Start
2019-09-01
Budget End
2020-08-31
Support Year
10
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Ohio State University
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
van Oosterwijk, Jolieke G; Buelow, Daelynn R; Drenberg, Christina D et al. (2018) Hypoxia-induced upregulation of BMX kinase mediates therapeutic resistance in acute myeloid leukemia. J Clin Invest 128:369-380
Fu, Qiang; Chen, Mingqing; Hu, Shuiying et al. (2018) Development and validation of an analytical method for regorafenib and its metabolites in mouse plasma. J Chromatogr B Analyt Technol Biomed Life Sci 1090:43-51
Bins, S; van Doorn, L; Phelps, M A et al. (2017) Influence of OATP1B1 Function on the Disposition of Sorafenib-?-D-Glucuronide. Clin Transl Sci 10:271-279
Park, I-K; Blum, W; Baker, S D et al. (2017) E3 ubiquitin ligase Cbl-b activates the p53 pathway by targeting Siva1, a negative regulator of ARF, in FLT3 inhibitor-resistant acute myeloid leukemia. Leukemia 31:502-505
Drenberg, Christina D; Gibson, Alice A; Pounds, Stanley B et al. (2017) OCTN1 Is a High-Affinity Carrier of Nucleoside Analogues. Cancer Res 77:2102-2111
Drenberg, Christina D; Buelow, Daelynn R; Pounds, Stanley B et al. (2017) Transcriptome profiling of patient derived xenograft models established from pediatric acute myeloid leukemia patients confirm maintenance of FLT3-ITD mutation. Leuk Lymphoma 58:247-250
Jarusiewicz, Jamie A; Jeon, Jae Yoon; Connelly, Michele C et al. (2017) Discovery of a Diaminopyrimidine FLT3 Inhibitor Active against Acute Myeloid Leukemia. ACS Omega 2:1985-2009
Jeon, Jae Yoon; Sparreboom, Alex; Baker, Sharyn D (2017) Kinase Inhibitors: The Reality Behind the Success. Clin Pharmacol Ther 102:726-730
Edginton, Andrea N; Zimmerman, Eric I; Vasilyeva, Aksana et al. (2016) Sorafenib metabolism, transport, and enterohepatic recycling: physiologically based modeling and simulation in mice. Cancer Chemother Pharmacol 77:1039-52
Drenberg, C D; Paugh, S W; Pounds, S B et al. (2016) Inherited variation in OATP1B1 is associated with treatment outcome in acute myeloid leukemia. Clin Pharmacol Ther 99:651-60

Showing the most recent 10 out of 24 publications